Irinotecan and vincristine with 131I-MIBG [iobenguane] for resistant/relapsed high-risk neuroblastoma, a phase I study.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Iobenguane (Primary) ; Irinotecan; Vincristine
- Indications Neuroblastoma
- Focus Adverse reactions
- 29 Aug 2014 Biomarkers information updated
- 12 Apr 2013 Planned end date changed from 1 Dec 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 14 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.